Biomind Labs Inc. announced that it has successfully completed the development of a novel sublingual formulation to be used in the Phase II trial for its 5-Metoxi-N,N-dimethyltryptamine (5-MeO-DMT)-based BMND08 candidate for the potential treatment of depression and anxiety in Alzheimer's disease.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1633 USD | +43.12% |
|
+43.12% | +63.30% |
1st Jan change | Capi. | |
---|---|---|
+63.30% | 12.21M | |
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease